Cara Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Given the paucity of novel pain drugs and the calamities surrounding Vioxx and OxyContin, Big Pharma has a keen interest in finding alternatives. Working within the G-protein coupled receptor superfamily, Cara Therapeutics hopes to oblige.